KRT88P and lymphoma: At baseline, HBsAg-positive lymphoma patients (Group B) had a remarkably higher qAnti-HBc level (3.48 ± 0.84 lg IU/mL) than that of HBsAg−/anti-HBc+ patients (Group C) (1.19 ± 0.90 lg IU/mL), p < 0.001.